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We previously reported that inhibition of mitochondrial complex I (CI) by rotenone induces marked increases in mitochondrial length and degree
of branching, thus revealing a relationship between mitochondrial function and shape. We here describe the first time use of fluorescence correlation
spectroscopy (FCS) to simultaneously probe mitochondrial mobility and intra-matrix protein diffusion, with the aim to investigate the effects of
chronic CI inhibition on the latter two parameters. To this end, EYFP was expressed in the mitochondrial matrix of human skin fibroblasts
(mitoEYFP) using baculoviral transduction and its diffusion monitored by FCS. This approach revealed the coexistence of moving and stationary
mitochondria within the same cell and enabled simultaneous quantification of mitochondrial velocity and mitoEYFP diffusion.When CI activity was
chronically reduced by 80% using rotenone treatment, the percentage of moving mitochondria and their velocity decreased by 30%. MitoEYFP
diffusion did not differ between moving and stationary mitochondria but was increased 2-fold in both groups of mitochondria following rotenone
treatment. We propose that the increase in matrix protein diffusion together with the increase in mitochondrial length and degree of branching
constitutes part of an adaptive response which serves to compensate for the reduction in CI activity and mitochondrial motility.
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breakdown of fatty acids, generation of heat and biosynthesisAbbreviations: ACF, autocorrelation function; CI, complex I or NADH:
ubiquinone oxidoreductase; F, degree of mitochondrial length and of branching;
FCS, fluorescence correlation spectroscopy; IMM, inner mitochondrial
membrane; mitoEYFP, enhanced yellow fluorescent protein targeted to the
mitochondrial matrix; Nc, number of mitochondria per cell; ROI, region of
interest; Δψ, mitochondrial membrane potential
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tides [1]. In addition to these ‘classical’ roles, mitochondria are
key players in cellular signaling through their involvement in
apoptosis, generation of reactive nitrogen- and oxygen species
(RNS/ROS), transduction of electrical signals and calcium
homeostasis [1–4]. Prerequisite for proper mitochondrial
functioning is a sufficiently negative potential difference across
the inner mitochondrial membrane (Δψ). This potential is
generated by the electron transport chain (complexes I to IV)
that, together with the Fo/F1-ATPase (complex V), constitutes
the oxidative phosphorylation (OXPHOS) system. This system
expels protons (complexes I, III and IV) out of the
mitochondrial matrix via controlled electron transfer from
NADH (complex I) and succinate (complex II) to oxygen
(complex IV) and uses the resulting electrochemical proton
gradient to drive the synthesis of ATP (complex V) [1,5]. Within
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constitutes the largest multisubunit assembly. Its malfunction is
associated with a wide variety of clinical syndromes ranging
from often early lethal disorders, of which Leigh disease, a
progressive encephalopathy, is the most frequent, to neurode-
generative disorders in adulthood, including Leber's hereditary
optic neuropathy and Parkinson's disease.
To better understand the cellular pathophysiology of CI
deficiency, we study fibroblasts from patients with identified
mutations in nuclear DNA-encoded subunits [3,4,6–8] and
healthy fibroblasts in which the pathological condition is mi-
micked by treatment with the specific CI inhibitor rotenone
[9,10]. Analysis of a large cohort of patient fibroblasts revealed
that the decrease in residual CI activity was less marked in cells
with elongated and more branched mitochondria [6]. Together
with our finding that mitochondrial length and degree of
branching were significantly increased in healthy fibroblasts
following chronic treatment with rotenone [9], this led us to
hypothesize that an increase in mitochondrial complexity might
constitute an adaptive response to the deficiency, thus suggesting
a link between mitochondrial functional state and shape.
With protein concentrations that readily exceed 300 mg/ml
[11], the mitochondrial matrix appears to be the most crowded
aqueous compartment of the cell. It can assume two extreme
configurations in which it either has a large (orthodox state) or
small (condensed state) volume. Evidence in the literature
suggests that changes in mitochondrial functional state are
paralleled not only by changes in shape but also in matrix
configuration [12–16]. For instance, mitochondrial uncouplers
and inhibitors of complex V have been shown to cause full
matrix condensation accompanied with fragmentation and
rounding [17,18]. It has been proposed that such a mechanism,
in which changes inmitochondrial functional state directly affect
matrix volume and mitochondrial shape, is used to regulate the
exchange of metabolites across the inner membrane and the
diffusion of matrix constituents [14,15,19]. As a consequence,
the rate of any biochemical process that is diffusion-limited will
be altered, independent of whether this process involves large
molecules, small molecules, or both [20].
The aim of the present study was to assess the relationship
between on the one hand CI deficiency and ensuing alterations in
mitochondrial morphology and on the other hand mitochondrial
motility and matrix solute diffusion. The two major challenges
facing live cell quantification of solute diffusion in the
mitochondrial matrix are the selective labeling of this compart-
ment with probes that do not bind to resident proteins and their
visualization in a compartment whose diameter is near the
resolution limit of the light microscope [21]. Therefore, we
selectively expressed EYFP within the mitochondrial matrix
(mitoEYFP) of healthy fibroblasts and determined its diffusion
properties using fluorescence correlation spectroscopy (FCS).
FCS is an optical technique with single-molecule sensitivity that
extracts information from fluctuations in molecule concentra-
tions within the focal volume [22–25]. In contrast to the
photobleaching approach used previously [17–19], FCS requires
only minute amounts of fluorescent proteins, making it well
suited to collect data under more physiological conditions [11].We observed that chronic partial CI inhibition by rotenone
decreased the percentage of moving mitochondria and their
velocity and increased the diffusion of mitoEYFP in both
moving and stationary mitochondria. The data obtained are
compatible with the idea that a reduction in CI activity results in
a decrease in mitochondrial movement which is compensated for
by an increase in mitochondrial length and degree of branching
[9] and an enhanced diffusion of matrix constituents.
2. Materials and methods
2.1. Cell lines
Fibroblasts were obtained from a healthy individual (#5120) according to the
relevant Institutional Review Boards and cultured in medium 199 with Earle's salt
supplemented with 10% (v/v) fetal calf serum, 100 IU/ml penicillin and 100 IU/ml
streptomycin in a humidified atmosphere of 95% air and 5% CO2 at 37 °C. For
analysis of mitochondrial morphology cells were cultured to 70% confluence on
glass cover slips (∅ 22 mm). For fluorescence correlation spectroscopy (FCS)
recordings, Lab-Tek® 8-well chambers (Nalgene Nunc International, IL, USA)
were used. Prior to microscopy experiments, culture medium was replaced with
colorless HEPES-Tris (HT) medium (132 mM NaCl, 4.2 mM KCl, 1 mM CaCl2,
1 mM MgCl2, 5.5 mM D-glucose and 10 mM HEPES, pH 7.4).
2.2. Quantitative analysis of mitochondrial morphology in living
fibroblasts
Mitochondria-targeted enhanced yellow fluorescent protein (mitoEYFP)
was expressed using a modified baculovirus vector, containing a mammalian-
active promoter driving the expression of a fusion between EYFP and the
targeting sequence of subunit VIII of cytochrome c oxidase (COX8), as
described previously [3]. Measurements were performed 3 days after the onset
of baculovirus transduction, when virtually all cells expressed the construct. The
virus remained present in the culture medium during the entire incubation
period. Quantitative analysis of mitochondrial morphology was carried out
using an Oz confocal microscope (Noran Instruments, Middleton, WI, USA) as
described in detail elsewhere [6,9,10].
2.3. Fluorescence correlation spectroscopy
Combined fluorescence correlation spectroscopy (FCS) and confocal
microscopy was performed on a ConfoCor II system (Carl Zeiss, Sliedrecht,
The Netherlands). MitoEYFP was excited using the 514 nm line of an Ar-ion
laser focused via a dichroic mirror and a Zeiss C-Apochromat objective (40×, N.
A. 1.2, water immersion) onto the sample. Fluorescence emission light was
guided via the dichroic mirror and a 545DF35 bandpass filter onto an avalanche
photodiode. After selection of mitochondrial regions of interest in confocal
mode, autocorrelation curves were acquired during 10 s at 20 °C. Because we
observed before that the diffusion time of EGFP was distinctly shorter at higher
laser intensities [26], laser output power was limited to 20 kW/cm2.
The positions of the pinhole and the correction ring of the objective lens
were optimized using an aqueous EYFP solution. Optimal settings were
considered to be reached when the highest molecular brightness was observed.
Fitting the autocorrelation curves of EYFP, of which the diffusion coefficient in
water is known, to Eq. (1) revealed that the FCS detection volume had radii of
0.253 μm and 1.37 μm for the equatorial (rxy) and axial radius (rz), respectively.
Intensity signals were software-correlated and individual autocorrelations were
displayed on-line. The autocorrelation function (ACF) describing j independent
molecular species diffusing freely in a 3D-Gaussian-shaped observation volume
(Veff=π3/2 rxy
2 rz) is given by:
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P
j
Fj ¼ 1 [26]. Autofluorescent proteins like EYFP show
additional fluorescence fluctuations due to conformational changes between
fluorescent and dark states [27]. The probability and relaxation time of the dark
state are given by T and τkin, respectively. The lateral diffusion time τdif,j
describes the residence time of a particle in the observation volume, which is
related to the translational diffusion coefficient:
sdiff ¼ r2xy=ð4dDtranÞ ð2Þ
The amplitude of the ACF, G(0), represents the average number of
molecules 〈N〉 found in the observation volume: G(0)−1=1/〈N〉. During
fitting, a single-component model (j=1) was evaluated first. This model
was considered valid when the residuals did not exceed 0.05 [22,28–31].
When the latter was not the case, the single-component model was
rejected and a two-component model (j=2) was evaluated using similar
criteria. Recordings displaying excessive bleaching (N5% over the full
duration of the recording) or high amplitude spikes were omitted from the
analysis.
2.4. Image analysis and statistics
Confocal images were processed and analyzed using Image Pro Plus 5.1
software (Media Cybernetics, Silver Spring, MD, USA). Numerical results
were visualized using Origin Pro 7.5 (Originlabs, Northampton, MA, USA) and
presented as the mean±SEM. Statistical differences were determined using
Student's unpaired t-test (Bonferroni-corrected) and significances indicated by
* (pb0.05) and ** (pb0.01).
2.5. Chemicals
Culture materials were obtained from Invitrogen (Breda, The Netherlands).
All other reagents were from Sigma (St. Louis, MO, USA).
3. Results
3.1. Bacoluviral transduction of fibroblasts with mitoEYFP
Changes in mitochondrial metabolic state can alter the
shape of the mitochondria and the volume of the mitochon-
drial matrix. As a consequence, also the diffusion character-
istics of matrix constituents may be altered. To test this idea,Table 1
Complex I activity, mitochondrial morphology, mitochondrial motility and mitoEYF
Control
Complex I
Biochemical activity a 100%
Mitochondrial morphology b
Diameter of filaments 0.85±0.0
Length and degree of branching (F) 100±1%
Number per cell (Nc) 100±2%
Mitochondrial motility
Moving mitochondria c 79% (N=
Speed of mitochondria (Dslow2)
d 0.06±0.0
MitoEYFP diffusion e
Stationary mitochondria (Dfast1) 22±2.1 μ
Moving mitochondria (Dfast2) 18±4.7 μ
Statistics: Significant differences with mitochondria in untreated control are indica
number of cells (mitochondrial morphology) or mitochondria (mitochondrial motilit
a Activities were measured previously [9] and expressed as % of control value.
b Morphology determined by analysis of mitoEYFP-expressing cells.
c The percentage represents the fraction of mitochondria displaying a double mito
d The value represents the apparent diffusion coefficient Dslow2 of mitoEYFP det
e Values depict the mitoEYFP translational diffusion coefficient within the mitocskin fibroblasts from a healthy individual (#5120) were
transfected with EYFP targeted to the mitochondrial matrix
(mitoEYFP). Previous functional and biochemical assays
revealed that cell line #5120 is representative of at least five
other healthy subjects [3,4,6,8,10,32,33].
To alter the metabolic state of the mitochondria,
fibroblasts were cultured in the continuous presence of the
specific CI inhibitor rotenone (100 nM) for 72 h. We
demonstrated previously [9] that this condition does not lead
to complete inhibition of CI (20% residual activity), which is
essential to avoid rotenone-induced cell killing [34]. More-
over, this treatment did not affect cell cycle phase, whereas it
caused a 2-fold increase in mitochondrial superoxide
production [9].
Quantification of mitochondrial morphology and number in
mitoEYFP-expressing cells was performed using confocal
microscopy and subsequent image analysis as described
previously [6,9,10]. It was found that the mitochondrial
formfactor (F), a combined measure of mitochondrial length
and degree of branching [10], was significantly increased in
rotenone-treated cells but that the number of mitochondria per
cell (Nc) was not altered (Table 1). The rotenone-induced
changes in mitochondrial morphology were in quantitative
agreement with previous results obtained in cells stained with
the fluorescent cation rhodamine 123 [9]. This demonstrates
that mitochondrial morphology was not altered by mere
expression of the fluorescent protein.
3.2. Quantification of mitoEYFP diffusion by fluorescence
correlation spectroscopy
A key parameter describing protein mobility is its transla-
tional diffusion coefficient [17,18,21,29,30,35]. To investigate
protein mobility in the mitochondrial matrix, we measured
mitoEYFP diffusion by fluorescence correlation spectroscopy
(FCS). MitoEYFP-expressing cells were visualized by confocalP diffusion in vehicle- and rotenone-treated control fibroblasts
Rotenone (100 nM, 72 h)
20%
5 μm (N=35) 0.76±0.03 μm (N=51)
(N=62) 143±5% (N=52)**
(N=62) 101±1% (N=52)
58) 47% (N=75)
1 μm2/s (N=46) 0.04±0.01 μm2/s (N=35)
m2/s (N=12) 33±1.3 μm2/s (N=40)**
m2/s (N=46) 36±5.5 μm2/s (N=35)*
ted in bold and by asterisks (*pb0.05; **pb0.01). Abbreviations: N indicates
y, mitoEYFP diffusion) analyzed.
EYFP mobility as determined by fluorescence correlation spectroscopy (FCS).
ermined by FCS.
hondrial matrix.
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randomly defined. Importantly, only ROIs still covering the
mitochondrion at the end of the recording period were analyzed
(Fig. 1A). On average, 3–6 mitochondrial ROIs were analyzed
per cell. For each ROI, fluorescence intensity fluctuations were
acquired during 10 s, after which the experimental autocorrela-
tion function (ACF) of the photodetector output was calculated.
To allow selection of the appropriate model for fitting the
ACF [36], we first assessed the mitochondrial diameter by
calculating the width at half maximal height of a 1 pixel
wide intensity profile perpendicular to the long axis of theFig. 1. Fluorescence correlation spectroscopy of mitoEYFP. (A) Contrast
optimized confocal image of a fibroblast transduced with a modified baculovirus
vector for expression of mitochondria-targeted EYFP (mitoEYFP). The
continuous line represents the cell boundary and crosses indicate regions were
FCS recordings were performed. Regions of interest (ROIs) were positioned on
mitochondrial filaments (1, 3–6) and in the nucleoplasm (2). The image was
taken at the end of the FCS measurement and shows that ROIs 1, 4 and 5 were
suitable for analysis of mitoEYFP diffusion. (B) Autocorrelation curve for
EYFP in buffer (smooth curve). No autocorrelation was observed in the nucleus
(ROI2). (C) Autocorrelation curve for EYFP in buffer (smooth curve) and
mitochondrion (ROI1).mitochondrial filament (see [36] and supplement of [37]. This
analysis revealed no difference between vehicle- and rotenone-
treated cells (Table 1) and the values obtained were in good
agreement with those determined in human dermal fibroblasts
by electron microscopy [38]. Calculating the ratio between the
minimal radii of a mitochondrion oriented in the plane of focus
(Table 1: 0.76/2=0.38 μm) and the FCS detection volume (see
Materials and methods: rxy=0.253 μm; rz=1.37 μm), revealed
values of 1.5 and 0.28 in the y- and z-direction, respectively.
Based on these results, we evaluated an ACF fitting model for
confined diffusion along the y- and z-axis (Ref. [36]; equation
45). However, this equation and model I (see Materials and
methods) fitted our experimental curves equally well, as
judged from χ2 statistics and visual inspection of the fit
residuals [22,28–31], and returned the same fit parameters.
This result was confirmed by fitting simulated data using the
same parameters and noise contribution as encountered in our
FCS measurements. Therefore, all ACFs were fitted to model
I. Of note, FCS was used previously to determine the
concentration of a GFP fusion protein in single immobilized
Escherichia coli bacteria [39], which have a diameter similar
to fibroblast mitochondria (0.4–0.7 μm; [40]).
To determine diffusion times (τdif) ACF curves were fitted
between τ=0.01 ms and τ=100 ms, a range associated with
translational diffusion [23]. The fast autocorrelation decay
observed around 20 μs was independent of the size of the
detection volume, which could be altered by varying the pinhole
diameter (data not shown). However, the decay(s) present in the
(sub-) millisecond region scaled with the size of the detection
volume and can therefore be attributed to diffusion processes.
In aqueous solution, EYFP displayed a single diffusion time
(τ=0.165±0.04 ms; Fig. 1B; smooth line; N=4), which was
equivalent (Eq. (2)) to a translational diffusion constant (D) of
92.3±0.22 μm2/s. Similar values have been reported previously
[30,35,41]. Inside the mitochondrial matrix, the ACF was
shifted to the right (Fig. 1C), indicating an increased correlation
time and consequent slower diffusion. In the nucleoplasm (Fig.
1B; ROI2) and cytosol (not shown), no autocorrelation was
detectable. Given the extreme (single-molecule) sensitivity of
the FCS technique [24], this rules out interference of auto-
fluorescence and demonstrates that mitoEYFP was exclusively
present within the mitochondrial matrix.
3.3. MitoEYFP diffusion in cultured human skin fibroblasts
In vehicle-treated fibroblasts, ∼20% of the mitochondria
showed a single mitoEYFP translational diffusion time (referred
to as τfast1), whereas the remainder displayed two translational
diffusion times (referred to as τfast2 and τslow2; Fig. 2A; left bar).
Importantly, both ‘types’ of mitochondria were present within
one and the same cell. Fig. 3A and B (left bars) depict the
corresponding translational diffusion coefficients, Dfast1 (22±
2.1 μm2/s; N=12 mitochondria) and Dfast2 (18±4.7 μm
2/s;
N=46 mitochondria), which were approximately 4-fold lower
than in aqueous solution (see above), and similar to those
previously determined by spot FRAP analysis of mitoGFP in a
variety of cell types including fibroblasts [17,19,21]. This
Fig. 2. Mitochondria display either a single or double mitoEYFP diffusion time. (A) Percentage of mitochondria in vehicle (CT)- and rotenone (ROT)-treated
fibroblasts, which displayed either a single (white bar) or double (black bar) mitoEYFP diffusion time. Mitochondria with a double diffusion time were absent in cells
treated with nocodazole (NOC). The number of mitochondria is indicated at the bottom of each bar (3 independent experiments). (B) Mitochondrial movement is
abolished upon depolymerization of the tubulin network by nocodazole (top right panel). Top images depict superimposed mitochondria at T=0 min (green) and
T=7 min (red). The difference between these images (lower panels) reflects the amount of mitochondrial movement. In vehicle-treated cells 65±2% of the
mitochondrial pixels differed between the green and red image, whereas in nocodazole-treated cells this difference was 4-fold reduced (14±1%). Abbreviations: CT,
vehicle-treated cells; ROT, rotenone-treated cells (100 nM, 72 h); NOC, nocodazole-treated cells (10 μg/ml, 2 h).
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0.01 μm2/s; N=46 mitochondria), depicted in Fig. 3C (left bar),
equalled the apparent diffusion coefficient for mitochondrial
movement estimated from mitochondrial displacement plots
(0.03-0.10 μm2/s; [42]). The latter result suggests that Dslow2
reflects mitochondrial velocity. To substantiate this idea
fibroblasts were treated with nocodazole (NOC; 10 μg/ml;
2 h), an established inhibitor of mitochondrial movement [42–
44]. Colocalization [10] and image subtraction analysis [44]
demonstrated that NOC treatment virtually abolished mitochon-
drial movement (Fig. 2B; upper and lower panels, respectively).Fig. 3. MitoEYFP diffuses faster in rotenone-treated cells. (A) Diffusion constant (D
(Dfast2) of EYFP in the matrix of moving mitochondria. (C) Apparent diffusion coe
differences (*pb0.05 and **pb0.01) with vehicle-treated control. The number of mi
experiments). Abbreviations: CT, vehicle-treated cells; ROT, rotenone-treated cellsSubsequent FCS measurement revealed that all mitochondria
displayed only a single mitoEYFP translational diffusion time
(Fig. 2A; right bar). Quantitatively, the translational diffusion
coefficient observed in the presence of NOC (Dnoc) equaled 22±
2 μm2/s (N=30 mitochondria) and was identical to Dfast1 and
Dfast2 in untreated fibroblasts (Table 1). These results confirm
that Dslow2 is a measure of mitochondrial velocity, whereas
Dfast1 and Dfast2 correspond to intra-matrix mitoEYFP diffusion
in stationary and moving mitochondria, respectively. Addition-
ally, our findings demonstrate that blocking mitochondrial
movement with nocodazole does not affect mitoEYFP diffusion.fast1) of EYFP in the matrix of stationary mitochondria. (B) Diffusion constant
fficient (Dslow2) representing mitochondrial movement. Statistically significant
tochondria that is analyzed is indicated at the bottom of each bar (3 independent
(100 nM, 72 h).
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is increased in rotenone-treated cells
Comparison of the number of mitochondria displaying either
a single or two translational diffusion times revealed that
rotenone treatment doubled the fraction of stationary mitochon-
dria from 21 to 53% (Fig. 2A; middle bar), whereas it reduced
the velocity of moving mitochondria (Dslow2) by 33% (Fig. 3C;
right bar). At the same time, rotenone treatment induced a 2-fold
increase in Dfast1 and Dfast2 (Fig. 3A and B; right bars),
demonstrating that mitoEYFP diffusion is faster in both moving
and stationary mitochondria. Both in vehicle- and rotenone-
treated cells Dfast1, Dfast2 and Dslow2 did not correlate with the
average number of molecules 〈N〉 detected in the observation
volume. For live cell FCS, the optimal intracellular concentra-
tion of fluorescent molecules is ∼1 nM [24,26,35], whereas the
upper limit is ∼100 nM [22,23,45]. Baculoviral transduction
resulted in the expression of 36 to 65 nM of mitoEYFP within
the mitochondrial matrix. This concentration was similar for
stationary and moving mitochondria.
4. Discussion
We previously demonstrated that a change in mitochondrial
metabolism, evoked by a decrease in CI activity, alters
mitochondrial shape [9]. Here we used fluorescence correlation
spectroscopy (FCS) to determine how this condition affects
mitochondrial mobility and protein diffusion within the matrix
of this organelle.
On average, 21% of the mitochondria displayed a single fast
translational diffusion coefficient of mitoEYFP (Dfast1) whereas
the remainder displayed both fast (Dfast2) and slow (Dslow2)
diffusion. This means that 21% of the mitochondria are stationary
whereas the remainder is moving. The fact that Dfast1 and Dfast2
did not differ indicates that matrix mitoEYFP diffusion is
similar in stationary and moving mitochondria.
Chronic partial complex I (CI) inhibition with a low
concentration of rotenone (100 nm, 72 h) decreased the
percentage of moving mitochondria from 79% to 50% and
reduced their velocity by 30%. This agrees with our previous
finding that acute rotenone application (1 μM) instantaneously
reduced mitochondrial motility [10].
Evidence has been provided that an increase in free cytosolic
Ca2+ concentration ([Ca2+]C) and/or drop in cytosolic ATP
concentration ([ATP]C) reduces mitochondrial motility [44,46].
However, resting [Ca2+]C in fura-2-loaded fibroblasts (see [3,4])
were not altered by chronic rotenone treatment (CT: 100±1%,
N=81 cells; ROT: 100±1%, N=89 cells), suggesting that the
rotenone-induced reduction in mitochondrial motility is not
mediated by [Ca2+]C. It has been demonstrated that chronic
rotenone treatment depolarizes Δψ [34] and, as a consequence,
can cause a large reduction in total cellular ATP levels [47].
Currently, we are not aware of a life-cell assay allowing
quantitative comparison of steady-state ATP levels between
control and rotenone-treated cells. However, in agreement with
the above results, treatment with the hormone bradykinin
significantly less stimulated ATP production in rotenone-treatedfibroblasts (CT: 100±5%, N=11 assays; ROT: 77±6%, N=9
assays; [3,4]). The fact that the rotenone-induced reduction in
hormone-induced ATP production (33%) was much less than
the reduction in CI activity (80%) is compatible with the
existence of a biochemical threshold effect [48].
Rotenone is able to arrest mammalian cells in metaphase by
preventing microtubule assembly [49,50]. Obviously, this
phenomenon could underlie the reduced mitochondrial motility
in rotenone-treated cells. However, in 143B osteosarcoma cells
chronic treatment with rotenone concentrations that produced
0–100% of CI inhibition, microtubule assembly was not
affected, and nuclear condensation was absent [34]. In line
with these findings, rotenone treatment (100 nM, 72 h) did not
detectably alter the cell cycle [9]. Similarly, nocodazole
treatment did not alter mitochondrial morphology in 143B
osteosarcoma cells within 4–24 h after drug application [51,52].
Therefore we propose that partial CI inhibition, induced by
chronic rotenone treatment, depolarizes Δψ, leading to a
decrease in [ATP]C and thus mitochondrial motility. Most
likely, this depolarization is relatively small, because the
fluorescent cation rhodamine 123 was well retained by
mitochondria in rotenone-treated cells [9,10].
Chronic partial CI inhibition induced a 2-fold increase in
translational diffusion of EYFP in the matrix of stationary and
moving mitochondria. This result suggests the transition to a
less condensed matrix configuration, possibly serving to
eliminate diffusion bottlenecks that would otherwise reduce
efficiency of ATP production [53]. It has been shown that the
mitochondrial matrix adopts the condensed configuration when
forced to produce energy by oxidative phosphorylation (in
galactose medium), whereas during glycolysis (in glucose
medium) it is in a more orthodox state [16]. Therefore our
findings might suggest that rotenone-treated fibroblasts switch
to a more glycolytic metabolism in an effort to compensate for
the loss in CI activity.
Currently, it is unclear how translational protein diffusion in
the mitochondrial matrix is regulated. However, our nocodazole
experiments clearly demonstrate that a marked reduction in
mitochondrial motility does not necessarily affect protein
diffusion in the mitochondrial matrix. This means that the
increased protein diffusion in the mitochondrial matrix of
rotenone-treated cells is tightly linked to the decrease in CI
activity. MitoEYFP will diffuse faster when matrix viscosity is
reduced, for instance by the influx of water across the
mitochondrial inner membrane [54]. Evidence in the literature
suggests a crucial role for the mitochondrial ATP-sensitive
potassium channel (mitoKATP) in mitochondrial matrix volume
regulation [55]. This channel is opened by a decrease in matrix
ATP concentration ([ATP]M; [56]), resulting in increased influx
of K+ and water. The mitoKATP channel can also be opened by
endogeneous peroxynitrite, which can be generated from the
reaction between superoxide and nitric oxide [57]. In this
context, we previously demonstrated that rotenone-induced CI
deficiency is associated with a marked increase in superoxide
levels in human skin fibroblasts [9]. It is likely that the degree of
rotenone-induced matrix swelling is only small since analysis of
the average mitochondrial diameter revealed no significant
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small increases in matrix volume without detectable increase in
mitochondrial diameter are not uncommon and can, for
instance, occur during fission and tubularization of cristae
[53]. Thus, opening of mitoKATP by a decrease in [ATP]M and/
or increase in peroxynitrite and the ensuing dilution of matrix
solutes and reduction of matrix viscosity, might explain the
faster matrix protein diffusion in rotenone-treated fibroblasts.
In conclusion, our results demonstrate that a decrease in CI
activity by rotenone similar to that observed in fibroblasts of
children with isolated CI deficiency [6], increases mitochondrial
length and degree of branching (this study and ref. [9]) and the
rate of protein diffusion in the mitochondrial matrix but reduces
mitochondrial motility. Spatial delivery of metabolites and
energy will be most efficient in the case of lengthy, highly
mobile mitochondria with a continuous matrix exhibiting a fast
translational diffusion of solutes [1,2]. This indicates that cells
with elongated mitochondria will benefit by far more from an
increase matrix solute diffusion than cells with shorter
mitochondria. Therefore, we propose that the increase in
mitochondrial length and degree of branching and rate of
matrix protein diffusion observed in rotenone-treated cells
constitute part of an adaptive response to counterbalance the
detrimental effects of the decrease in CI activity (i.e. reduced CI
activity and mitochondrial motility).
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